Despite Recent Volatility, Biotech Stocks Look Poised to Pop

Biotechnology investors are no strangers to volatility, and Tuesday’s price action was no exception. Followers of gene therapy companies watched one of the most popular names in the industry lose approximately one-third of its value due to patient safety concerns. As alluded to above, shares of Spark Therapeutics dropped sharply in Tuesday’s trading session due to heightened patient safety concerns surrounding a hemophilia gene therapy trial. (Story originally posted August 8, 2018)

Source: Despite Recent Volatility, Biotech Stocks Look Poised to Pop

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.